161 related articles for article (PubMed ID: 35228520)
1. miR-32 promotes MYC-driven prostate cancer.
Scaravilli M; Koivukoski S; Gillen A; Bouazza A; Ruusuvuori P; Visakorpi T; Latonen L
Oncogenesis; 2022 Mar; 11(1):11. PubMed ID: 35228520
[TBL] [Abstract][Full Text] [Related]
2. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
3. lncRNA PCAT19 promotes the proliferation of laryngocarcinoma cells via modulation of the miR-182/PDK4 axis.
Xu S; Guo J; Zhang W
J Cell Biochem; 2019 Aug; 120(8):12810-12821. PubMed ID: 30868666
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium.
Latonen L; Scaravilli M; Gillen A; Hartikainen S; Zhang FP; Ruusuvuori P; Kujala P; Poutanen M; Visakorpi T
Am J Pathol; 2017 Nov; 187(11):2546-2557. PubMed ID: 28827140
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.
Coarfa C; Fiskus W; Eedunuri VK; Rajapakshe K; Foley C; Chew SA; Shah SS; Geng C; Shou J; Mohamed JS; O'Malley BW; Mitsiades N
Oncogene; 2016 May; 35(18):2345-56. PubMed ID: 26364608
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-1205, encoded on chromosome 8q24, targets EGLN3 to induce cell growth and contributes to risk of castration-resistant prostate cancer.
Wang Y; Li X; Liu W; Li B; Chen D; Hu F; Wang L; Liu XM; Cui R; Liu R
Oncogene; 2019 Jun; 38(24):4820-4834. PubMed ID: 30808975
[TBL] [Abstract][Full Text] [Related]
7. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
Kiener M; Chen L; Krebs M; Grosjean J; Klima I; Kalogirou C; Riedmiller H; Kneitz B; Thalmann GN; Snaar-Jagalska E; Spahn M; Kruithof-de Julio M; Zoni E
BMC Cancer; 2019 Jun; 19(1):627. PubMed ID: 31238903
[TBL] [Abstract][Full Text] [Related]
8. Functional roles of miR-625-5p and miR-874-3p in the progression of castration resistant prostate cancer.
Aktan Ç; Çal Ç; Kaymaz B; Selvi Günel N; Kıpçak S; Özel B; Gündüz C; Şahin Küçükaslan A; Aygüneş Jafari D; Kosova B
Life Sci; 2022 Jul; 301():120603. PubMed ID: 35508255
[TBL] [Abstract][Full Text] [Related]
9. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-144-3p inhibits cell proliferation and promotes apoptosis in castration-resistant prostate cancer by targeting CEP55.
You B; Zhang KC
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7660-7670. PubMed ID: 30536308
[TBL] [Abstract][Full Text] [Related]
11. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
13. Targeting PDK4 inhibits breast cancer metabolism.
Guda MR; Asuthkar S; Labak CM; Tsung AJ; Alexandrov I; Mackenzie MJ; Prasad DV; Velpula KK
Am J Cancer Res; 2018; 8(9):1725-1738. PubMed ID: 30323966
[TBL] [Abstract][Full Text] [Related]
14. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.
Josson S; Gururajan M; Hu P; Shao C; Chu GY; Zhau HE; Liu C; Lao K; Lu CL; Lu YT; Lichterman J; Nandana S; Li Q; Rogatko A; Berel D; Posadas EM; Fazli L; Sareen D; Chung LW
Clin Cancer Res; 2014 Sep; 20(17):4636-46. PubMed ID: 24963047
[TBL] [Abstract][Full Text] [Related]
15. LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis.
Cui Z; Wang Q; Deng MH; Han QL
Cancer Biomark; 2022; 34(1):41-53. PubMed ID: 34542064
[TBL] [Abstract][Full Text] [Related]
16. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
17. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
Sjöblom L; Saramäki O; Annala M; Leinonen K; Nättinen J; Tolonen T; Wahlfors T; Nykter M; Bova GS; Schleutker J; Tammela TL; Lilja H; Visakorpi T
PLoS One; 2016; 11(3):e0150241. PubMed ID: 26939004
[TBL] [Abstract][Full Text] [Related]
18. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
Chen W; Yao G; Zhou K
J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
[TBL] [Abstract][Full Text] [Related]
19. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
20. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
